It is very uncertain whether siponimod changes number of participants with relapses at 6 months compared with placebo (very low certainty).
Siponimod may leads to lower participants with disability worsening at 6 months compared with placebo (low certainty).
Siponimod showed no clear difference in number of participants who withdrew due to AEs at 6 months compared with placebo (low certainty).
Siponimod may leads to lower annualised relapse rate compared with placebo (low certainty).
It is very uncertain whether siponimod changes mean number of gadolinium‐enhancing lesions on T1‐weighted brain MRI… compared with placebo (very low certainty).
Siponimod may leads to lower mean number of new lesions or enlarged pre‐existing lesions on… compared with placebo (low certainty).
Siponimod showed no clear difference in number of participants with at least one SAE at 6 months compared with placebo (low certainty).